Welcome to ZENBEXUS REMS (Risk Evaluation and Mitigation Strategy)
What is ZENBEXUS REMS?
A Risk Evaluation and Mitigation Strategy (REMS) is designed to manage known or potentially serious risks associated with a drug. It is required by the US Food and Drug Administration (FDA) to ensure that the benefits of a drug outweigh its risks.
Treatment with ZENBEXUS™ (iberdomide) may result in embryo-fetal toxicity. Therefore, the FDA requires that all prescribers and pharmacies certify with ZENBEXUS REMS. All patients must enroll in and comply with all the safe-use requirements of ZENBEXUS REMS.
Prescribers can log into the REMS Portal 
to complete certification in the program.
Once certified, use the portal to manage REMS tasks and patients.
The Pharmacy Authorized Representative can log into the REMS Portal to complete certification.
Once certified, use the portal to invite pharmacy staff members to manage REMS tasks and patients.
Prescribers
Prescribers must be certified in ZENBEXUS REMS in order to prescribe ZENBEXUS.
Pharmacies
Pharmacies must be certified in ZENBEXUS REMS in order to dispense ZENBEXUS.
Patients
Patients must be enrolled in ZENBEXUS REMS in order to receive ZENBEXUS.
Contact Information
| Suspected pregnancies |  1-888-423-5436 (REMS Call Center) |
| Suspected adverse events (side effects) or product quality complaints associated with ZENBEXUS |
|
